BACKGROUND: In high-resource settings, the HIV-attributable risk of myocardial infarction (MI) is higher among women than among men. The extent to which unique mechanisms contribute to MI risk among women vs. men with HIV remains unclear. METHODS: Subclinical coronary atherosclerotic plaque characteristics-including high-risk morphology plaque features-were compared among 48 HIV-infected women [48 (41, 54) years] and 97 HIV-infected men [48 (42, 52) years] on stable antiretroviral therapy (ART) without known cardiovascular disease. These individuals had previously completed coronary computed tomography angiography and metabolic/immune phenotyping as part of a prospective study. RESULTS: Extending previous analyses, now focusing exclusively on ART-treated participants, we found that HIV-infected women had a lower prevalence of any subclinical coronary atherosclerotic plaque (35% vs. 62%, P = 0.003) and a lower number of segments with plaque (P = 0.01), compared with HIV-infected men. We also report for the first time that ART-treated HIV-infected women had a lower prevalence of high-risk positively remodeled plaque (25% vs. 51%, P = 0.003) and a lower number of positively remodeled plaque segments (P = 0.002). In models adjusting for cardiovascular risk factors, we further showed that male sex remained associated with any coronary plaque [odds ratio 3.8, 95% confidence interval: (1.4 to 11.4)] and with positively remodeled plaque [odds ratio 3.7, 95% confidence interval: (1.4, 10.9)]. CONCLUSIONS: ART-treated HIV-infected women (vs. HIV-infected men) had a lower prevalence and burden of subclinical coronary plaque and high-risk morphology plaque. Thus, unique sex-specific mechanisms beyond subclinical plaque may drive the higher HIV-attributable risk of MI among women vs. men.
BACKGROUND: In high-resource settings, the HIV-attributable risk of myocardial infarction (MI) is higher among women than among men. The extent to which unique mechanisms contribute to MI risk among women vs. men with HIV remains unclear. METHODS: Subclinical coronary atherosclerotic plaque characteristics-including high-risk morphology plaque features-were compared among 48 HIV-infectedwomen [48 (41, 54) years] and 97 HIV-infectedmen [48 (42, 52) years] on stable antiretroviral therapy (ART) without known cardiovascular disease. These individuals had previously completed coronary computed tomography angiography and metabolic/immune phenotyping as part of a prospective study. RESULTS: Extending previous analyses, now focusing exclusively on ART-treated participants, we found that HIV-infectedwomen had a lower prevalence of any subclinical coronary atherosclerotic plaque (35% vs. 62%, P = 0.003) and a lower number of segments with plaque (P = 0.01), compared with HIV-infectedmen. We also report for the first time that ART-treated HIV-infectedwomen had a lower prevalence of high-risk positively remodeled plaque (25% vs. 51%, P = 0.003) and a lower number of positively remodeled plaque segments (P = 0.002). In models adjusting for cardiovascular risk factors, we further showed that male sex remained associated with any coronary plaque [odds ratio 3.8, 95% confidence interval: (1.4 to 11.4)] and with positively remodeled plaque [odds ratio 3.7, 95% confidence interval: (1.4, 10.9)]. CONCLUSIONS:ART-treated HIV-infectedwomen (vs. HIV-infectedmen) had a lower prevalence and burden of subclinical coronary plaque and high-risk morphology plaque. Thus, unique sex-specific mechanisms beyond subclinical plaque may drive the higher HIV-attributable risk of MI among women vs. men.
Authors: P Elliott Miller; Sabina A Haberlen; Thomas Metkus; Panteha Rezaeian; Frank Palella; Lawrence A Kingsley; Mallory D Witt; Richard T George; Lisa P Jacobson; Todd T Brown; Matthew Budoff; Wendy S Post Journal: Atherosclerosis Date: 2015-06-18 Impact factor: 5.162
Authors: Hyung-Bok Park; Ran Heo; Bríain Ó Hartaigh; Iksung Cho; Heidi Gransar; Ryo Nakazato; Jonathon Leipsic; G B John Mancini; Bon-Kwon Koo; Hiromasa Otake; Matthew J Budoff; Daniel S Berman; Andrejs Erglis; Hyuk-Jae Chang; James K Min Journal: JACC Cardiovasc Imaging Date: 2015-01
Authors: Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Doris Hsinyu Chen; Márton Kolossváry; Shaoguang Chen; Hong Lai; Hsin-Chieh Yeh; Shenghan Lai Journal: Am J Drug Alcohol Abuse Date: 2020-09-29 Impact factor: 3.829
Authors: Mabel Toribio; Tomas G Neilan; Magid Awadalla; Lauren A Stone; Adam Rokicki; Corinne Rivard; Connor P Mulligan; Diana Cagliero; Lindsay T Fourman; Takara L Stanley; Jennifer E Ho; Virginia A Triant; Tricia H Burdo; Michael D Nelson; Lidia S Szczepaniak; Markella V Zanni Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Sara E Looby; Amy Kantor; Tricia H Burdo; Judith S Currier; Carl J Fichtenbaum; Edgar T Overton; Judith A Aberg; Carlos D Malvestutto; Gerald S Bloomfield; Kristine M Erlandson; Michelle Cespedes; Esper G Kallas; Mar Masiá; Alice C Thornton; Mandy D Smith; Jacqueline M Flynn; Emma M Kileel; Evelynne Fulda; Kathleen V Fitch; Michael T Lu; Pamela S Douglas; Steven K Grinspoon; Heather J Ribaudo; Markella V Zanni Journal: Clin Infect Dis Date: 2022-10-12 Impact factor: 20.999
Authors: Andreas Knudsen; Kristina Thorsteinsson; Thomas E Christensen; Philip Hasbak; Rasmus Sejersten Ripa; Inge Panum; Anne-Mette Lebech; Andreas Kjaer Journal: Open Forum Infect Dis Date: 2018-09-11 Impact factor: 3.835
Authors: Chris T Longenecker; Milana Bogorodskaya; Seunghee Margevicius; Rashidah Nazzinda; Marcio Sommer Bittencourt; Geoffrey Erem; Sophie Nalukwago; Moises A Huaman; Brian B Ghoshhajra; Mark J Siedner; Steven M Juchnowski; David A Zidar; Grace A McComsey; Cissy Kityo Journal: J Int AIDS Soc Date: 2022-01 Impact factor: 5.396
Authors: Katherine Kentoffio; Matthew S Durstenfeld; Mark J Siedner; Cissy Kityo; Geoffrey Erem; Isaac Ssinabulya; Brian Ghoshhajra; Marcio S Bittencourt; Chris T Longenecker Journal: Int J Cardiol Cardiovasc Risk Prev Date: 2022-06-08